Curevac and gsk start clinical development of second-generation covid-19 vaccine candidate, cv2cov

Phase 1 dose-escalation study started at clinical sites in the u.s. milestone demonstrates curevac's and gsk's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases tÜbingen, germany and boston, ma / accesswire / march 30, 2022 / curevac n.v. (nasdaq:cvac), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced that the first participant was dosed in a phase 1 study of covid-19 second-generation mrna vaccine candidate, cv2cov, developed in collaboration with gsk.
CVAC Ratings Summary
CVAC Quant Ranking